Table 1.
Patient characteristics pre- and post-matching.
| Variables | Prematch | Postmatch | ||||
|---|---|---|---|---|---|---|
| eGFR < 30 mL/min n = 23 |
eGFR ≥ 30 mL/min n = 183 |
p Value | eGFR < 30 mL/min n = 23 |
eGFR ≥ 30 mL/min n = 23 |
p Value | |
| eGFR, median (IQR), mL/min | 22.3 (18.7–26.3) | 64.5 (47.7–78.2) | <0.01 a | 22.3 (18.7–26.3) | 47.1 (45.0–50.0) | <0.01 a |
| Age, median (IQR), years | 80 (74–86) | 72 (54–81) | 0.02 a | 80 (74–86) | 81 (78–88) | 0.37 a |
| Sex (male/female) | 14/9 | 125/58 | 0.47 b | 14/9 | 11/12 | 0.38 b |
| Severity of COVID-19 | ||||||
| Mild | 11 | 47 | 0.14 b | 11 | 6 | 0.31 b |
| Moderate | 9 | 103 | 9 | 13 | ||
| Severe/critical | 3 | 33 | 3 | 4 | ||
| Risk factor for progression to severe COVID-19 (%) | 23 (100.0) | 164 (89.6) | 0.70 b | 23 (100.0) | 23 (100.0) | 1.00 b |
| Age > 60 years | 22 | 60 | 22 | 23 | ||
| Hypertension | 10 | 64 | 10 | 8 | ||
| Cardiac disease | 6 | 18 | 6 | 5 | ||
| Cancer | 6 | 33 | 6 | 7 | ||
| Diabetes | 5 | 47 | 5 | 8 | ||
| Chronic lung disease | 5 | 39 | 5 | 7 | ||
| Chronic kidney disease | 5 | 2 | 5 | 1 | ||
| Cerebrovascular disease | 3 | 20 | 3 | 2 | ||
| Immunosuppression | 3 | 20 | 3 | 3 | ||
| Smoking | 3 | 73 | 3 | 3 | ||
| Dementia | 2 | 16 | 2 | 8 | ||
| Obesity | 0 | 24 | 0 | 2 | ||
| HIV | 0 | 0 | 0 | 0 | ||
| Mental disorders | 0 | 2 | 0 | 0 | ||
| Concomitant nephrotoxic drug usage (%) | 5 (21.7) | 18 (9.8) | 0.10 b | 5 | 5 | 1.00 b |
| TMP-SMX | 2 | 0 | 2 | 0 | ||
| Loop diuretics | 2 | 14 | 2 | 4 | ||
| Tacrolimus/cyclosporine | 1 | 3 | 1 | 0 | ||
| Vancomycin | 0 | 1 | 0 | 1 | ||
a Mann–Whitney U test, b Pearson’s χ2 test; eGFR: estimated glomerular filtration rate; IQR: interquartile range; COVID-19: coronavirus disease 2019; TMP-SMX: trimethoprim-sulfamethoxazole.